A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis

Journal of the American Academy of Dermatology

Volumn 54, Issue 5, 2006, Pages 880-882

  Chung, Lorinda ^a   Fiorentino, David ^b  

^a Division of Immunology and Rheumatology

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOMODULATING AGENT; UNIPROST;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG TOLERABILITY; FEMALE; FINGER; GANGRENE; HUMAN; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; SCLERODERMA; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; ULCER;

ADULT; EPOPROSTENOL; FEMALE; FINGERS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; SKIN ULCER; TREATMENT OUTCOME;

EID: 33646099173     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2006.02.004     Document Type: Article

References (11)

1. Ferri C., Valentini G., Cozzi F., Sebastiani M., Michelassi C., La Montagna G., et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine 81 (2002) 139-153
2. Hummers L., and Wigley F. Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma. Rheum Dis Clin North Am 29 (2003) 293-313
3. Desai R., and Korn J. Diagnosis and management of Raynaud phenomenon. J Musculoskel Med 20 (2003) 124-135
4. Korn J., Mayes M., Matucci Cerinic M., Rainisio M., Pope J., Hachulla E., et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arth Rheum 50 (2004) 3985-3993
5. Gore J., and Silver R. Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis. Ann Rheum Dis 64 (2005) 1387
6. Wigley F., Wise R., Seibold J., McCloskey D., Kujala G., Medsger T., et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 120 (1994) 199-206
7. Badesch D., Tapson V., McGoon M., Brundage B., Rubin L., Wigley F., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 132 (2000) 425-434
8. Simonneau G., Barst R., Galie N., Naeije R., Rich S., Bourge R., et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165 (2002) 800-804
9. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arth Rheum 23 (1980) 581-590
10. Fries J., Spitz P., Kraines R., and Holman H. Measurement of patient outcome in arthritis. Arth Rheum 23 (1980) 137-145
11. Steen V., and Medsger Jr. T. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arth Rheum 40 (1997) 1984-1991